116 related articles for article (PubMed ID: 3521959)
21. Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
Rasmusson GH; Reynolds GF; Steinberg NG; Walton E; Patel GF; Liang T; Cascieri MA; Cheung AH; Brooks JR; Berman C
J Med Chem; 1986 Nov; 29(11):2298-315. PubMed ID: 3783591
[TBL] [Abstract][Full Text] [Related]
22. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
23. Selective inhibition of prostatic tumor 5 alpha-reductase by a 4-methyl-4-azasteroid.
Kadohama N; Karr JP; Murphy GP; Sandberg AA
Cancer Res; 1984 Nov; 44(11):4947-54. PubMed ID: 6488158
[TBL] [Abstract][Full Text] [Related]
24. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
25. Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients.
Mowszowicz I; Melanitou E; Doukani A; Wright F; Kuttenn F; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1983 Jun; 56(6):1209-13. PubMed ID: 6841558
[TBL] [Abstract][Full Text] [Related]
26. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
George FW; Johnson L; Wilson JD
Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
[TBL] [Abstract][Full Text] [Related]
27. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
[TBL] [Abstract][Full Text] [Related]
28. Effect of a new 5 alpha-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate.
Brooks JR; Berman D; Glitzer MS; Gordon LR; Primka RL; Reynolds GF; Rasmusson GH
Prostate; 1982; 3(1):35-44. PubMed ID: 7079196
[TBL] [Abstract][Full Text] [Related]
29. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
30. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates.
Hirosumi J; Nakayama O; Chida N; Inami M; Fagan T; Sawada K; Shigematsu S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):365-73. PubMed ID: 7734405
[TBL] [Abstract][Full Text] [Related]
31. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
32. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
[TBL] [Abstract][Full Text] [Related]
33. LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.
Neubauer BL; Best KL; Blohm TR; Gates C; Goode RL; Hirsch KS; Laughlin ME; Petrow V; Smalstig EB; Stamm NB
Prostate; 1993; 23(3):181-99. PubMed ID: 8234065
[TBL] [Abstract][Full Text] [Related]
34. Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy.
Geldof AA; Meulenbroek MF; Dijkstra I; Bohlken S; Rao BR
J Cancer Res Clin Oncol; 1992; 118(1):50-5. PubMed ID: 1729259
[TBL] [Abstract][Full Text] [Related]
35. Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats.
Yasuda N; Fujino K; Shiraji T; Nambu F; Kondo K
Jpn J Pharmacol; 1997 Jul; 74(3):243-52. PubMed ID: 9268084
[TBL] [Abstract][Full Text] [Related]
36. Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin.
Mellin TN; Busch RD; Rasmusson GH
J Steroid Biochem Mol Biol; 1993 Feb; 44(2):121-31. PubMed ID: 8439517
[TBL] [Abstract][Full Text] [Related]
37. Possible mechanisms of androgen resistance in 5 alpha-reductase deficiency: implications for the physiological roles of 5 alpha-reductases.
Hodgins MB
J Steroid Biochem; 1983 Jul; 19(1B):555-9. PubMed ID: 6887883
[TBL] [Abstract][Full Text] [Related]
38. Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.
Tuttle RM; Loop S; Jones RE; Meikle AW; Ostenson RC; Plymate SR
Prostate; 1994 May; 24(5):229-36. PubMed ID: 8170835
[TBL] [Abstract][Full Text] [Related]
39. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
40. 4-MAPC, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight, DNA, and prostatein concentrations.
Ghusn HF; Shao TC; Klima M; Cunningham GR
J Androl; 1991; 12(5):315-22. PubMed ID: 1765567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
